Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer

医学 内科学 癌症 肿瘤科 队列 单变量分析 多元分析 比例危险模型 免疫疗法 回顾性队列研究 疾病
作者
Na Zhuo,Chang Xin Liu,Qi Zhang,Jian Li,Xiaotian Zhang,Jifang Gong,Ming Shian Lu,Zhi Peng,Jun Zhou,Xicheng Wang,Xi Jiao,Yujiao Wang,Yanni Wang,Mengting Gao,Lin Shen,Zhihao Lü
出处
期刊:JAMA network open [American Medical Association]
卷期号:5 (3): e224637-e224637 被引量:33
标识
DOI:10.1001/jamanetworkopen.2022.4637
摘要

Importance: With the expanding use of immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer, the occurrence of acquired resistance (AR) has gradually emerged. However, the progression patterns and survival of patients with AR to ICIs are still unknown. Objective: To explore the characteristics and prognosis of AR after ICI therapy in patients with advanced GI cancer. Design, Setting, and Participants: This cohort study screened patients with advanced GI cancer treated with ICIs between January 14, 2016, and December 31, 2020, at Peking University Cancer Hospital. Initial response was defined as complete response, partial response, or stable disease longer than 6 months as assessed by Response Evaluation Criteria in Solid Tumors version 1.1. Progression was also based on Response Evaluation Criteria in Solid Tumors version 1.1. Progression or death after the initial response was defined as AR. Oligoprogression of AR was defined as 2 or more disease sites progression. The current status of AR in GI cancer and the patterns of AR and its prognosis were evaluated. The site of AR and subsequent management were also assessed. Data were analyzed from June to August 2021. Exposures: Patients in the cohort were treated with mono-ICI or combination therapy. Main Outcomes and Measures: Kaplan-Meier analyses and log-rank tests were conducted for overall survival analyses. Univariate and multivariate Cox analyses were conducted to determine the prognostic implications of each variable. Results: Of the 1124 patients who received ICIs, 373 (33.2%) patients (282 men [75.6%]; median [IQR] age, 62 [54-68] years) achieved an initial response, and 173 (46.4%) patients (137 men [79.2%]; median [IQR] age, 61 [54-67] years) developed AR. Almost all patients (167 patients [96.5%]) developed AR within 24.0 months. Progression patterns of AR were most commonly oligoprogression (122 patients [70.5%]) rather than polymetastatic progression (38 patients [22.0%]) and were associated with a good prognosis (38.5 vs 14.0 months; hazard ratio, 0.37; 95% CI, 0.18-0.74; P < .001). Lymph nodes (101 patients [58.4%]) appeared to be the most common site of AR. Management after AR was mainly systemic therapy (96 patients [55.5%]). Conclusions and Relevance: Oligoprogression was the most common pattern of AR progression, and lymph nodes were the most susceptible site for AR. Further study will be needed to determine the most favorable management for AR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
muzi871203完成签到,获得积分10
刚刚
LIU发布了新的文献求助10
刚刚
荼蘼发布了新的文献求助10
1秒前
jkjkjkjkhs完成签到,获得积分10
1秒前
2秒前
狂野冰蝶完成签到,获得积分10
2秒前
Liwx完成签到,获得积分10
3秒前
4秒前
小慈完成签到,获得积分10
4秒前
猫儿的日子是悠哉悠哉的完成签到,获得积分10
4秒前
5秒前
冷酷成风发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
香蕉觅云的应助被正直未来采纳,获得10
6秒前
阿努比斯的应助被lsw采纳,获得30
6秒前
老六发布了新的文献求助10
6秒前
7秒前
李金桥完成签到 ,获得积分10
7秒前
BAEKHYUNLUCKY发布了新的文献求助10
8秒前
8秒前
jefeer完成签到,获得积分10
9秒前
今后的应助被要减肥的朋友采纳,获得10
9秒前
10秒前
AA发布了新的文献求助10
10秒前
荼蘼发布了新的文献求助30
10秒前
Yangqx007完成签到,获得积分10
10秒前
jasmine970000发布了新的文献求助200
10秒前
11秒前
罗小黑发布了新的文献求助10
12秒前
13秒前
汉堡包的应助被喵喵拳采纳,获得10
14秒前
秋风的应助被YU采纳,获得10
14秒前
zzh完成签到,获得积分20
14秒前
皮蛋发布了新的文献求助10
16秒前
生动万言发布了新的文献求助10
16秒前
18秒前
无花果的应助被科研通管家采纳,获得10
20秒前
uTwTu的应助被科研通管家采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241